◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Shree Ganesh Remedies Limited (SGRL) Financial History

Name: Shree Ganesh Remedies Limited (SGRL) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Shree Ganesh Remedies Limited (SGRL) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Ankleshwar, India with about 224 employees. Its market capitalization is roughly ₹9 billion. In the fiscal year ended 2026-03-31, SGRL reported ₹1.1B in revenue and ₹178M in net income.

Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally.

Interactive charts & full statements →

SGRL Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹1.1B	₹1.1B	₹1.2B	₹902M	—
Gross Profit	₹660M	₹703M	₹663M	₹431M	—
Operating Income (EBIT)	₹251M	₹302M	₹357M	₹203M	—
Net Income	₹178M	₹231M	₹281M	₹170M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SGRL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹144M	₹332M	₹211M	₹303M	₹247M
Gross Profit	₹123M	₹190M	₹148M	₹177M	₹159M
Operating Income (EBIT)	₹9M	₹86M	₹41M	₹70M	₹49M
Net Income	₹11M	₹63M	₹31M	₹50M	₹34M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SGRL Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	—	—	(₹6M)	(₹6M)	(₹16M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SGRL Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹2.1B	₹1.9B	₹1.7B	₹1.4B	—
Total Liabilities	₹447M	₹468M	₹488M	₹549M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SGRL viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

1681 · Consun Pharmaceutical Group Limited — HK$11 billion
4512 · Wakamoto Pharmaceutical Co.,Ltd. — JPY 10 billion
ANUHPHR · Anuh Pharma Limited — ₹9 billion
4524 · Morishita Jintan Co., Ltd. — JPY 9 billion
2005 · SSY Group Limited — HK$8 billion
WANBURY · Wanbury Limited — ₹8 billion
APTX · Apotex Health Corp. — C$8 billion
BAFNAPH · Bafna Pharmaceuticals Limited — ₹8 billion

← SGQX All “S” companies SGRO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.